Urovant Sciences GmbH clinical trials
Acquired by Sumitomo Pharma Co., Ltd., Dec 27, 2019 · source ↗
The registry lists 11 studies whose lead sponsor is Urovant Sciences GmbH. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 15, 2026.
Before and after it joined Sumitomo Pharma Co., Ltd.
- First submitted before Urovant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.
- 9
- First submitted after Urovant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.
- 2
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Urovant Sciences GmbH11 studies
Something wrong with this grouping? Tell us on the Sumitomo Pharma Co., Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 11 of 11. All Sumitomo Pharma Co., Ltd. studies →
- Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CICRecruitingNCT05491525Phase 2/3
Sponsor listed in the registry: Urovant Sciences GmbH · First submitted after Urovant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.
- Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)CompletedNCT05067478
Sponsor listed in the registry: Urovant Sciences GmbH · First submitted after Urovant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.
- Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic HyperplasiaCompletedNCT04103450Phase 3
Sponsor listed in the registry: Urovant Sciences GmbH · First submitted before Urovant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.
- Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)CompletedNCT03902080Phase 3
Sponsor listed in the registry: Urovant Sciences GmbH · First submitted before Urovant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.
- URO-902 in Female Subjects With Overactive Bladder and Urge Urinary IncontinenceCompletedNCT04211831Phase 2
Sponsor listed in the registry: Urovant Sciences GmbH · First submitted before Urovant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.
- Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel SyndromeCompletedNCT03806127Phase 2
Sponsor listed in the registry: Urovant Sciences GmbH · First submitted before Urovant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.
- An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).CompletedNCT03583372Phase 3
Sponsor listed in the registry: Urovant Sciences GmbH · First submitted before Urovant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.
- A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)CompletedNCT03492281Phase 3
Sponsor listed in the registry: Urovant Sciences GmbH · First submitted before Urovant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.
- Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene for EDCompletedNCT02713789Phase 2
Sponsor listed in the registry: Urovant Sciences GmbH · First submitted before Urovant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.
- Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor OveractivityTerminatedNCT00495053Phase 1
Sponsor listed in the registry: Urovant Sciences GmbH · First submitted before Urovant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.
- Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene TransferCompletedNCT01870037Phase 1
Sponsor listed in the registry: Urovant Sciences GmbH · First submitted before Urovant Sciences GmbH became part of Sumitomo Pharma Co., Ltd.